Sandalwood giant can smell big dollars in warts more

ViroXis Corporation Announces expanded board of directors and advisors more

ITClamp Hemorrhage Control System from Innovative Trauma Care more

ViroXis Corporation Initiates Phase II Clinical Trial of Novel Botanical Topical Treatment for HPV Skin Warts more

Vidacare Corp. aims to ease that pain with the OnControl Bone Marrow System. The Bronze winner of The Wall Street Journal's Technology Innovation Awards, and winner of the Medical-Devices category, the product allows doctors to more quickly and precisely take samples from inside the bone more

DNAtrix, Inc., the Houston-based biotechnology company developing targeted adenovirus-based oncolytic virus products, announced today a merger with VectorLogics, Inc. more

Innovative Trauma Care (ITC) has received regulatory approval from Health Canada for commercial sale of its first product, the IT Clamp™ more

BiO2 Medical, Inc and R&D and manufacturing operations in Golden, Colorado, has recently secured $12M in Series C funding more

ENTrigue Surgical Announces Sinus Surgery Collaboration with fiagon GmbH more

Soluble Therapeutics, Inc. Awarded ~$1MM NIH Grant for Continued Development of the HSC Technology for Protein Formulation more

Vidacare Corporation Creates New Medical Director of Clinical Affairs Position for Intraosseous Vascular Access Division more

BiO2 Medical Granted CE Mark for the Angel™ Catheter, the First IVC Filter with a Prophylactic Use Indication.

BiO2 Medical, Inc. a Texas based medical device manufacturer with corporate offices in San Antonio, Texas, and R&D and manufacturing operations in Golden, Colorado, announced today that it has received CE Mark approval for the Angel™ Catheter, a Nitinol Inferior Vena Cava (IVC) filter, permanently attached to a central venous catheter (CVC) for the use of preventing Pulmonary Embolism (PE) in critically ill patients. This novel IVC filter/CVC combination device is the first IVC filter with a prophylactic use indication, and allows attending physicians the ability to place an IVC filter bedside in the Intensive Care Unit (ICU), in a procedure resembling a routine CVC placement procedure.

According to Luis F. Angel, MD, BiO2 Medical's Chief Medical Officer and inventor of the Angel™ Catheter, "Obtaining the CE clearance for commercialization of the Angel™ Catheter in Europe is a significant step in our goal to provide an alternative for critically ill patients at high risk of Pulmonary Embolism (PE).  It also validates a long and complex process of extensive testing for the use of our device as a prophylaxis against PE."

"With CE Mark approval for the Angel™ Catheter, and preliminary safety data from a First in Man clinical study, these are exciting times for the entire team at BiO2 Medical.  We've been working diligently over the past several years to bring this product to market, and I am justifiably impressed and proud of everyone who has helped to bring this life saving device to market," stated Christopher E. Banas, BiO2 Medical's Chairman and Chief Executive Officer.

For more information regarding BiO2 Medical and the Angel™ Catheter, please visit www.bio2medical.com back

NMP Neuwirth Medical Products GmbH signs an exclusive distribution partnership for the Ventera, MediENT, ENTact, Synaero, and SerpENT in Germany

ENTrigue Surgical participates in the first Global Update on FESS, The Sinuses, and The Nose in Vienna, Austria

BiO2 Medical Announces First in Man Clinical Study more

BiO2 Medical Secures Series B Round Funding more

Study Finds Intraosseous Infusion is Equivalent to Intravenous Infusion During Therapeutic Hypothermia more

Vidacare Corporation to Sponsor 2012 British Journal of Nursing Haematology Award Category more